Company intelligence / Profile preview
Gannex Pharma Co., Ltd.
Shanghai, Shanghai, Chinagannexpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Gannex has multiple drug candidates in clinical development for NASH and other indications. Their most advanced drug candidate has reached Phase 3. ASC42 (FXR agonist) has completed patient enrollment for Phase II clinical trial for PBC with topline data expected by the end of 2023. ASC41 (THR-β agonist) has shown positive Phase I results with LDL-C and triglyceride reductions in NAFLD patients.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Gannex Pharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gannex Pharma Co., Ltd..